Sign in

You're signed outSign in or to get full access.

LC

Li Chen

Research Analyst at H.C. Wainwright

New York, NY, US

Li Chen is an Equity Research Associate at H.C. Wainwright & Co., specializing in biotechnology and life sciences sector analysis. Chen contributes to research coverage of emerging biotech companies, leveraging a blend of scientific expertise and financial analysis to support investment decisions, although specific performance metrics and company coverage are not publicly detailed. With a career focus on equity research in the life sciences, Chen provides crucial support in evaluating clinical data and market potential, having joined H.C. Wainwright following academic and industry experience in biomedical research. Professional credentials such as FINRA registration and securities licenses are not available in the public domain for Li Chen as of now.

Li Chen's questions to HSBC HOLDINGS (HSBC) leadership

Question · Q4 2025

Li Chen requested further information on the growth opportunities and stronger synergies in the wealth management business following the privatization of Hang Seng Bank, and asked about the outlook for wealth balances and wealth management margins.

Answer

Group CFO Georges Elhedery reiterated that Hang Seng Bank will retain its brand, independent customer proposition, and branch network. He stated that privatization enables better efficiencies in cross-selling and aligning back-office capabilities, not related to customer proposition. Group Chief Risk and Compliance Officer Pam Kaur added that post-privatization, the arm's-length restriction is removed, allowing broader product offerings, cross-referrals, and seamless investment across both brands to lean into Hong Kong's growth and macro opportunities, including cross-border wealth.

Ask follow-up questions

Fintool

Fintool can predict HSBC HOLDINGS logo HSBC's earnings beat/miss a week before the call

Li Chen's questions to AFMD leadership

Question · Q3 2024

Asked about the development strategy for AFM28, including potential acceleration and positioning (frontline vs. later-line), and the rationale for choosing between unengineered NK cells versus CAR-NK cells for a combination therapy.

Answer

The company's preferred strategy for AFM28 is to first consolidate the monotherapy signal for a potential accelerated approval path in later-line AML, which is faster than a frontline trial. For combinations, they prefer using an allogeneic NK cell product over CAR-NKs, citing lower cost, simpler manufacturing, and the ability to recruit the patient's own NK cells for a dual attack.

Ask follow-up questions

Fintool

Fintool can predict AFMD logo AFMD's earnings beat/miss a week before the call